Related Experiment Video
Updated: Jul 14, 2026
Author Spotlight: Treating Knee Osteoarthritis with Tuina - A New Perspective
Published on: January 12, 2024
Biologics in the treatment of active Psoriatic arthritis in China: a network meta-analysis and cost-effectiveness
Ouyang Xie1,2, Meiyu Wu1,2, Andong Li1,2
1Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Background:
Biologics are recommended for use in patients with psoriatic arthritis (PsA) after the failure of conventional systemic disease-modifying anti-rheumatic drugs (csDMARDs). However, compared to csDMARDs, biologics are significantly more expensive. The aim of this study was to evaluate the cost-effectiveness of biologic treatments for active PsA patients who have failed treatment with csDMARDs, from the perspective of the Chinese healthcare system.
Research Design And Methods:
A discrete event simulation model was constructed to estimate health and economic outcomes of patients. The seven biologics recommended by the Chinese psoriasis treatment guidelines were included in the evaluation. One-way and probabilistic sensitivity analysis were performed to ensure that our results were robust.
Results:
Our results found that compared to the standard of care (SoC) and all other biologics strategies, secukinumab (SEC) had the highest quality-adjusted life years, and at a willingness-to-pay (WTP) threshold of US $38,161 per QALY, SEC was the most cost-effective option, with an incremental cost-effectiveness ratio of $14,968 per QALY. One-way sensitivity analysis and probabilistic sensitivity analysis confirmed the robust of this result.
Conclusions:
From the perspective of the Chinese healthcare system, biologics are estimated to be cost-effective compared to SoC. Among these, SEC is the most cost-effective option.
